Robert H. Lurie Comprehensive Cancer Center

Clinical research site in Chicago, Illinois · 250 E SUPERIOR ST, SUITE 520, CHICAGO, IL 60611-2914 · (312) 472-5823 · Website

As of July 2026, 12 paid clinical trials are recruiting at Robert H. Lurie Comprehensive Cancer Center in Chicago, Illinois. Active studies at this site cover conditions such as PIK3CA Mutation, HER2- Negative Breast Cancer and Hormone Receptor Positive Tumor. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Robert H. Lurie Comprehensive Cancer Center (12)

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for PIK3CA Mutation

52 locations incl. Gilbert

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06982521·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

for AML

36 locations incl. Gilbert

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06001788·Phase 1·Recruiting·Listed Aug 2023

Apply to this trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for Acute Myeloid Leukemia

44 locations incl. Phoenix

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT05735184·Phase 1·Recruiting·Listed Feb 2023

Apply to this trial

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

for Extensive Stage-small Cell Lung Cancer

25 locations incl. Birmingham

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06362252·Phase 1, Phase 2·Recruiting·Listed Apr 2024

Apply to this trial

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

for Lymphoma

14 locations incl. Aurora

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT07015242·Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

for Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

22 locations incl. Los Angeles

Sponsor: Servier Bio-Innovation LLC

Sex: All·Age: 18+

Code: NCT06127407·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial